Biotech Values

[DewDiligence]

FMI’s 4Q14 CC covered a lot of ground and is well worth a listen for shareholders and prospective shareholders. Based on the company’s 2015 guidance, I think the stock would be languishing now were it not for the Roche tender offer.

Due to the multifaceted nature of the Roche collaboration, FMI now has many more moving parts and hence it’s hard to predict where the share price goes in the medium term once Roche’s tender offer is completed.

One notable disclosure from the CC: Roche won’t be logging any international sales of FoundationOne or FoundationOne Heme until 2H16.